We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

Hutchison China MediTech

Timing is right for a Hong Kong debut

Update | 30 May 2019


Getting back on the front foot

Update | 21 May 2019


SCIB2 to use new nanoparticle formulation

Lighthouse | 20 May 2019

Mereo BioPharma

Focus shifts back to imminent data

Update | 08 May 2019


Dosing advances to second cohort in CARMA Phase I

Lighthouse | 08 May 2019


Building momentum

Update | 07 May 2019


Phase II melanoma study with SCIB1 to start in Q219

Lighthouse | 25 April 2019


At the forefront of the cell therapy revolution

Update | 24 April 2019

Mereo BioPharma

Path cleared for partnering of acumapimod (BCT-197)

Lighthouse | 16 April 2019

Hutchison China MediTech

Proposed listing in Hong Kong and global offering

Lighthouse | 15 April 2019
1 2 3 4 5 6 7 8 9 10 11 12 13 14
136 results found.